Inside Precision Medicine July 17, 2024
Vertex Pharmaceuticals announced a $945 million-plus collaboration with Orum Therapeutics to develop a different kind of conditioning regimen than the chemotherapies that are currently used. Vertex will use Orum’s dual-precision targeted protein degradation (TPD²®) technology platform to discover targeted conditioning agents for use with gene editing therapies.
Orum has granted Vertex rights to conduct research using its TPD² approach to developing DACs, next-generation versions of antibody-drug conjugates (ADCs) which use antibodies to precisely deliver small molecule targeted protein degrader payloads to cancer cells and other targeted biological therapies.
Following a research period for each target, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, manufacture, and commercialize DACs developed with Orum’s TPD² technology for that...
Today's Sponsors
Today's Sponsor